证券之星消息，11月13日南向资金减持13.03万股春立医疗（01858.HK）。近5个交易日中，获南向资金 增持的有2天，累计净增持1.88万股。近20个交易日中，获南向资金增持的有14天，累计净增持211.97万 股。截至目前，南向资金持有春立医疗（01858.HK）4507.51万股，占公司已发行普通股的47.36%。 北京市春立正达医疗器械股份有限公司是一家主要从事植入性骨科医疗器械研发、生产及销售业务的中 国公司。该公司主要产品为关节假体产品及脊柱类植入产品。关节假体产品涵盖髋、膝、肩、肘四大人 体关节。脊柱类植入产品为脊柱内固定系统的全系列产品组合。该公司的产品出口至亚洲、南美洲、非 洲、大洋洲及欧洲等多个国家和地区。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-13 | 4507.51万 | -13.03万 | -0.29% | | 2025-11-12 | 4520.53万 ...

Group 1 - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 14,000 shares on November 13, 2025 [1] - Over the past 5 trading days, there has been a cumulative net reduction of 192,000 shares by southbound funds [1] - In the last 20 trading days, southbound funds have reduced their holdings for 20 days, totaling a net reduction of 1.733 million shares [1] Group 2 - As of now, southbound funds hold 110 million shares of HeartCare Medical-B, accounting for 4.55% of the company's total issued ordinary shares [1] - The company specializes in providing comprehensive medical solutions for structural heart disease, focusing on transcatheter and surgical solutions [2] - HeartCare Medical's product pipeline includes TAVI series products, AnchorMan left atrial appendage occluder products, transcatheter mitral valve products, transcatheter tricuspid valve products, and surgical support products [2]

微创医疗科学有限公司是一家主要从事医疗器械的销售、生产、研究及开发（R&D）的投资控股公 司。该公司通过八个分部开展业务。心血管介入业务分部包括植入器械、通路器械等产品。骨科医疗器 械业务分部包括关节重建、脊柱等器械。心律管理（CRM）业务分部包括起搏器、除颤器等器械。大 动脉及外周血管介入业务分部包括"L-REBOA"主动脉阻断球囊等产品。神经介入业务分部包括脑动脉 粥样硬化狭窄、弹簧圈等产品。结构性心脏病业务分部包括经导管主动脉瓣植入术等产品。手术机器人 业务分部从事手术机器人器械的制造及研发。外科医疗器械业务分部从事外科医疗器械的制造及研发。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-13 | 8.92亿 | 27.00万 | 0.03% | | 2025-11-12 | 8.92亿 | -103.81万 | -0.12% | | 2025-11-11 | 2766.8 | -69 ...

Core Viewpoint - Insulet (PODD) is experiencing solid improvement in earnings estimates, which is likely to positively impact its stock price momentum [1][2]. Earnings Estimate Revisions - The trend in estimate revisions reflects growing analyst optimism regarding Insulet's earnings prospects, which historically correlates with stock price movements [2]. - For the current quarter, Insulet is expected to earn $1.47 per share, representing a year-over-year increase of +27.8%. Over the last 30 days, seven estimates have been revised upward, leading to a 12.07% increase in the Zacks Consensus Estimate [6]. - For the full year, the earnings estimate stands at $4.89 per share, indicating a +50.9% change from the previous year. Eight estimates have moved higher in the past month, resulting in a 6.1% boost to the consensus estimate [7][8]. Zacks Rank and Performance - Insulet currently holds a Zacks Rank 1 (Strong Buy), supported by favorable estimate revisions. This ranking is associated with a strong historical performance, with Zacks 1 stocks averaging a +25% annual return since 2008 [3][9]. - The stock has gained 7.8% over the past four weeks, indicating investor confidence in its earnings growth prospects [10].

Core Viewpoint - ST Zhongzhu announced that Qiongqing Cheng Meihua Tenglong Qifei Investment Partnership intends to acquire 10.38% of the company's shares for 403 million yuan, marking a significant investment by a well-known venture capital figure, Wu Shichun [1][4][11]. Group 1: Investment Details - Meihua Investment will become the second-largest shareholder of ST Zhongzhu after the acquisition, with the first-largest shareholder being Shenzhen Landi Technology Development Co., holding 19.08% [4][7]. - The shares will be acquired at a price of 1.95 yuan per share, with a total transaction value of 403 million yuan [4][11]. - Prior to this transaction, Meihua Investment did not hold any shares in ST Zhongzhu [7]. Group 2: Company Performance - As of November 13, ST Zhongzhu's stock price was 2.18 yuan per share, reflecting a 4.81% increase, with a total market capitalization of 4.344 billion yuan [3]. - The company has faced financial difficulties, with negative net profits reported from 2022 to 2024, and a significant decline in revenue of 18.35% year-over-year for 2024 [12][13]. - For the first three quarters of 2025, ST Zhongzhu reported a net profit of -33.785 million yuan, indicating a 63.44% increase in losses compared to the previous year [13][16]. Group 3: Market Activity - ST Zhongzhu experienced stock price volatility during the transaction period, with a notable price increase of 4.64% on November 11, leading to consecutive limit-up closures on November 12 and 13 [9][10]. - The trading activity on November 13 showed significant participation from brokerage firms, indicating heightened investor interest [10].

【导读】ST中珠10.38% 股份 将转让梅花投资，11月13日涨停并登上龙虎榜 中国基金报记者 闻言 11月13日晚间，ST中珠发布公告称，共青城梅花腾龙起飞投资合伙企业（有限合伙）（以下简称梅花投资）拟 以 4.03亿元 自有资金 ， 受让公司10.38%的股份。 公开资料显示，梅花投资的 执行事务合伙人 吴世春，系 国内 创投圈知名人士，旗下梅花创投参投 了 理想汽车等企业。 | 姓名 | 性别 | 职务 | 国籍 | 长期居住地 | 是否取得其他国家 | | --- | --- | --- | --- | --- | --- | | | | | | | 或 其他居留权 | | 吴世春 | 男 | 执行事务合伙人 | 中国 | 北京 | 否 | 截至11月13日收盘，ST中珠股价报2.18元/股，涨幅达4.81%，总市值为43.44亿元。 | 公司名称 | 共青城梅花腾龙起飞投资合伙企业(有限合伙) | | --- | --- | | 统一社会信用代码 | 91360405MAENA00D47 | | 成立时间 | 2025年7月3日 | | 执行事务合伙人 | 吴世春 | | 企业类型 | 有限合伙企 ...

Core Viewpoint - Shanghai Ladder Medical Technology Co., Ltd. has announced that its self-developed "Implantable Wireless Brain-Computer Interface System" has officially entered the special review procedure for innovative medical devices by the National Medical Products Administration, marking a significant step in the industrialization of brain-computer interface technology in China [1][2]. Group 1: Product Development and Approval - The implantable brain-computer interface is the first invasive product to enter the "green channel" in China, which allows for accelerated review and approval processes, reduced registration fees, and comprehensive support for innovation [1][2]. - The product integrates key technologies for neural signal acquisition, decoding, and control, enabling precise motor signal recognition, which opens new avenues for functional replacement for patients with motor disabilities [2][6]. - The product must meet three core conditions to enter the "green channel": compliance with intellectual property rights, a standardized research process, and outstanding technical and clinical value [3]. Group 2: Market Potential and Growth - The brain-computer interface industry is transitioning from laboratory research to clinical and commercial stages, with the Chinese market projected to reach 3.2 billion yuan in 2024, growing at a rate of 18.8%, and expected to reach 6.14 billion yuan by 2028, with a compound annual growth rate of 17.7% [7]. - The implementation of policies to promote the innovation and development of the brain-computer interface industry is expected to enhance the industry's innovation capabilities and establish a reliable industrial system by 2030 [7][8]. - The recent approval of the first industry standard for brain-computer interface medical devices in China aims to unify terminology and provide a foundation for research, registration, and regulation [8]. Group 3: Industry Challenges and Dynamics - Despite the promising outlook, the transition from clinical research to commercial viability for brain-computer interfaces faces challenges such as technology maturity verification, collaborative development across the industry chain, and market awareness cultivation [8][9]. - Recent fluctuations in A-share brain-computer interface concept stocks indicate market volatility, with companies experiencing significant price changes following news related to the industry [8].

Core Points - The company, Guangzhou Maipu Regenerative Medicine Technology Co., Ltd., announced that its actual controller and major shareholder, Mr. Yuan Yuyu, has pledged part of his shares [2] Summary by Category - **Share Pledge Details** - The number of shares pledged is 2,600,000 [2]

（文章来源：证券日报） 证券日报网讯 11月13日晚间，透景生命发布公告称，公司控股子公司武汉康录生物技术股份有限公司 申报的境内体外诊断试剂注册申请于近日获得了国家药品监督管理局的受理，产品名称：PML/RARA 融合基因检测试剂盒（荧光原位杂交法）。 ...

证券日报网讯 11月13日晚间，透景生命发布公告称，公司及全资子公司上海透景诊断科技有限公司于 近期收到中华人民共和国国家知识产权局颁发的1项发明专利证书，专利名称：杂交瘤细胞株10B9E3-1 和2D5C12-1及其分泌抗体的应用。 （文章来源：证券日报） ...